<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814110</url>
  </required_header>
  <id_info>
    <org_study_id>UMB 143-20899 P</org_study_id>
    <nct_id>NCT02814110</nct_id>
  </id_info>
  <brief_title>Efficacy Safety of Granulocyte Colony-stimulating Factor Treatment Children and Adolescents With Muscular Dystrophy</brief_title>
  <official_title>Efficacy and the Safety of Granulocyte Colony-stimulating Factor Treatment in Children and Adolescents With Muscular Dystrophy: An Open Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Importance: Currently the gold standard treatment for ambulant patients is corticosteroids.
      Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of
      satellite cells, the regulation of myoblast proliferation, and the differentiation and
      promotion of muscle regeneration and repair.

      Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with
      muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy ,
      Fascioscapulohumeral dystrophy.

      Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies
      will be included in an open study. Patients wheelchair-bound and and mobile and
      self-independent can participate in the study. Patients also treated with steroids can
      participate in this study. Clinical examination and physiotherapeutic and laboratory tests
      will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days
      during the 1st, 2nd, 3rd. 6th and 12th months. Manual muscle testing (Lovett test) of the
      upper and lower extremities, isometric force with the hand dynamometer, and the 6MWT (six
      minute walk test) are measured before and after therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Importance: Currently the gold standard treatment for ambulant patients is corticosteroids.
      Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of
      satellite cells, the regulation of myoblast proliferation, and the differentiation and
      promotion of muscle regeneration and repair.

      Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with
      muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy ,
      Fascioscapulohumeral dystrophy.

      Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies
      will be included in an open study. Patients wheelchair-bound and and mobile and
      self-independent can participate in the study. Patients also treated with steroids can
      participate in this study. Clinical examination and physiotherapeutic and laboratory tests
      will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days
      during the 1st, 2nd, 3rd. 6th and 12th months. Blood is sampled before G-CSF administration
      and on the 5th day of each treatment cycle.

      During each cycle of G-CSF administration physical therapy is also applied. Abdominal
      ultrasonography with a spleen assessment is performed before and after 7 days of G-CSF
      administration. Spirometry and electrocardiographic record are also performed. Side effects
      of G-CSF treatment will be assessed.

      Manual muscle testing (Lovett test) of the upper and lower extremities, isometric force with
      the hand dynamometer, and the 6MWT (six minute walk test) are measured before and after
      therapy. MRI of the gastrocnemius muscles will performed at the beginning and at the end of
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety based on number of participants with adverse events.</measure>
    <time_frame>Seven years</time_frame>
    <description>Adverse events will be monitored and scored for severity and related to the Granulocyte Colony-Stimulating Factor administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength in patients with muscular dystrophy</measure>
    <time_frame>Seven years</time_frame>
    <description>The assessment of muscle strength of the upper and lower limbs by Lovett test. The evaluation isometric force of upper limbs with the hand dynamometer.
Distance measurement in a 6-minute walk test (6MWT) by feet or wheelchair,6MWT before and after therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory investigations in patients with muscular dystrophy</measure>
    <time_frame>Seven years</time_frame>
    <description>Blood count: Red blood cells 10^6/µL; Hemoglobin g/dl, Leucocytes 10^3/µL, Platelets 10^3/µL; biochemistry CRP - C Reactive Protein - mg/L; creatinine - mg/dL; glucose mg/dL, electrolytes, AST- U/L; ALT - U/L; cholesterol mg/dL; fibrinogen - mg/dL, partial thromboplastin time - sec; prothrombin time - sec, creatine kinase - U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal ultrasonography in patients with muscular dystrophy</measure>
    <time_frame>Seven years</time_frame>
    <description>Abdominal ultrasonography with a spleen measurement will be done before and after G-CSF administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic records in patients with muscular dystrophy</measure>
    <time_frame>Seven years</time_frame>
    <description>Electrocardiographic records wiil ibe done in patients with muscular Dystrophy before and after G-CSF administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Increase Muscle Strength in Patients With Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Granulocyte colony-stimulating factor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte colony-stimulating factor (Filgrastim)</intervention_name>
    <description>Drug administration</description>
    <arm_group_label>Granulocyte colony-stimulating factor</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Muscular dystrophy - Duchenne muscular dystrophy, Becker muscular dystrophy,
             Fascioscapulohumeral dystrophy

          -  age 5-15

        Exclusion Criteria:

          -  non- muscular dystrophy

          -  age below 5 years

          -  age over 15 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wojciech Kulak, MD,PhD,Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Bialystok, Bialystok, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Kulak, MD,PhD,Prof</last_name>
    <phone>+48603512723</phone>
    <email>kneur2@wp.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dorota Sienkiewicz, MD,PhD</last_name>
    <phone>+48857450601</phone>
    <email>sdorota11@op.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatric Rehabilitation</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-2174</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Kułak, MD, PhD, Prof.</last_name>
      <phone>+48603512723</phone>
      <email>kneur2@wp.pl</email>
    </contact>
    <contact_backup>
      <last_name>Dorota Sienkiewicz, MD, PhD</last_name>
      <phone>+48857450601</phone>
      <email>sdorota11@op.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Wojciech Kułak, MD, PhD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorota Sienkiewicz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bożena Okurowska-Zawada, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grażyna Paszko-Patej, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janusz Wojtkowski, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karolina Sochoń, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamila Okulczyk, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Kalinowska, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Sienkiewicz D, Kułak W, Paszko-Patej G, Okurowska-Zawada B, Sienkiewicz J, Kułak P. Biochemical Changes in Blood of Patients with Duchenne Muscular Dystrophy Treated with Granulocyte-Colony Stimulating Factor. Biomed Res Int. 2019 Mar 13;2019:4789101. doi: 10.1155/2019/4789101. eCollection 2019.</citation>
    <PMID>31001554</PMID>
  </results_reference>
  <results_reference>
    <citation>Sienkiewicz D, Kułak W, Okurowska-Zawada B, Paszko-Patej G, Wojtkowski J, Sochoń K, Kalinowska A, Okulczyk K, Sienkiewicz J, McEachern E. Efficacy and the Safety of Granulocyte Colony-Stimulating Factor Treatment in Patients with Muscular Dystrophy: A Non-Randomized Clinical Trial. Front Neurol. 2017 Oct 26;8:566. doi: 10.3389/fneur.2017.00566. eCollection 2017.</citation>
    <PMID>29123500</PMID>
  </results_reference>
  <results_reference>
    <citation>Eljaszewicz A, Sienkiewicz D, Grubczak K, Okurowska-Zawada B, Paszko-Patej G, Miklasz P, Singh P, Radzikowska U, Kulak W, Moniuszko M. Effect of Periodic Granulocyte Colony-Stimulating Factor Administration on Endothelial Progenitor Cells and Different Monocyte Subsets in Pediatric Patients with Muscular Dystrophies. Stem Cells Int. 2016;2016:2650849. doi: 10.1155/2016/2650849. Epub 2015 Dec 6.</citation>
    <PMID>26770204</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulocyte colony-stimulating factor</keyword>
  <keyword>muscular dystrophy</keyword>
  <keyword>muscle strength</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

